Notably, emerging studies report that pharmacological inhibition of RORγ in vitro and in vivo exerts potent antitumor activity in multiple cancer types, such as castration-resistant prostate cancer88, pancreatic adenocarcinoma89, and triple-negative breast cancer90. This evidence concerns the gene RORC and cancer.